Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 1035 Cambridge St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ernexatx.com
- Keywords
- Cellular Reprogramming, Synthetic mRNA, Gene Editing, Non-Viral Nucleic Acid Delivery, Human Derived Mixed Cytokines.
- HQ
- Cambridge, Massachusetts
Ernexa Therapeutics Questions
Ernexa Therapeutics's website is https://ernexatx.com
Ernexa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ernexa-therapeutics
Ernexa Therapeutics has
6 employees.
View email and phone details for 6
employees at Ernexa Therapeutics.
Ernexa Therapeutics's industry is
Biotechnology Research
Ernexa Therapeutics's top competitors are
Cellular Origins,
Matica Biotechnology, Inc.,
Allovir,
Factor Bioscience Inc.,
Mongoose Bio Inc.,
Omniabio,
Virica Biotech,
Exmoor Pharma,
Scorpion Therapeutics,
Immatics.
Ernexa Therapeutics's categories are Biotechnology Research
Ernexa Therapeutics's founding year is 1994
